Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 16/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091514 | 0.89 | TNFRSF1A (0.58) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6094560 | 0.88 | TNFRSF1A (0.48) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6090983 | 0.83 | TNFRSF1A (0.47) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6092377 | 0.81 | TNFRSF1A (0.51) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6091906 | 0.81 | TNFRSF1A (0.51) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6091924 | 0.79 | TNFRSF1A (0.50) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6111525 | 0.78 | TNFRSF1A (0.81) | TNFRSF1A | |
| SCHEMBL6091721 | 0.77 | TNFRSF1A (0.54) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6091940 | 0.76 | TNFRSF1A (0.52) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6091629 | 0.75 | TNFRSF1A (0.49) | TNFRSF1AKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | TNFRSF1A 4880/4885KDM4E 1931/4885ALDH1A1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.